AustraliaHealth

Wellnex Life (ASX:WNX) provided shareholders with an update on its ongoing turnaround strategy.

Mayne Pharma Group (ASX:MYX) has inaugurated its newly expanded manufacturing facility in Salisbury, South Australia.

Recce Pharmaceuticals (ASX:RCE), a developer of a new class of synthetic anti-infectives, has received an Advanced Overseas Finding from the Australian Department of Industry, Science and Resources

Artrya (ASX:AYA), a medical technology company commercialising its Salix AI-powered cloud platform for near real-time, point-of-care assessment and management of coronary artery disease, has announced that Tanner Health has commenced commercial use of the Salix Coronary Plaque module, generating the first fee-per-scan revenues for the company.

Rhythm Biosciences (ASX:RHY) has commenced commercialisation of its flagship blood-based colorectal cancer test, ColoSTAT, following the update and renewal of its ISO15189:2022 laboratory accreditation.

The test will initially be offered as an alternative for symptomatic individuals where stool-based screening is unsuitable, unavailable, or not preferred, addressing a significant unmet clinical need.

AI-enabled pharmaceutical company Algorae Pharmaceuticals (ASX:1AI) has received the comprehensive in silico synergy predictions generated by its AlgoraeOS v2 platform, covering over 500,000 potential combinations of cannabidiol with more than 3,000 approved and investigational drugs across 170 cell lines.

4DMedical (ASX:4DX) has secured $30.2 million in funding by entering an underwriting agreement with Bell Potter Securities, ensuring the full exercise of its 4DXO listed options. 

Under the agreement, any unexercised options at expiry will be subscribed by the underwriter, guaranteeing the total funding amount.